ASAlkananda Sahoo

Alkananda Sahoo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alkananda Sahoo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tumor thickness and depth of invasion in squamous cell carcinoma of tongue as indicators of the loco-regional spread of the disease: A preliminary study

    by Rupsa Das, Satya Ranjan Misra, Satya Sundar Gajendra Mohapatra, Pravakar Bahinipati, Smita Rani Priyadarshini, Alkananda Sahoo, Debahuti Mishra, Anamika Rai


  • Open Access

    Can Immunoexpression of Cancer Stem Cell Markers Prognosticate Tongue Squamous Cell Carcinoma? A Systematic Review and Meta-Analysis

    by Sayantanee Chaudhury, Swagatika Panda, Neeta Mohanty, Saurav Panda, Diksha Mohapatra, Ravishankar Nagaraja, Alkananda Sahoo, Divya Gopinath, Natalia Lewkowicz, Barbara Lapinska

    The objective was to evaluate the association of the immunoexpression of cancer stem cell (CSC) markers with clinicopathological and survival outcomes in tongue squamous cell carcinoma (TSCC) patients. This systematic review and meta-analysis [PROSPERO (CRD42021226791)] included observational studies that compared the association of clinicopathological and survival outcomes with CSC immunoexpression in TSCC patients. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) were used as outcome measures. Six studies identified the association with three surface markers (c-MET, STAT3, CD44) and four transcription markers (NANOG, OCT4, BMI, SOX2). The odds of early-stage presentation were 41% (OR = 0.59, 95% CI 0.42–0.83) and 75% (OR = 0.25; 95% CI 0.14–0.45) lower in CSC and SOX2 immuno-positive cases than immuno-negative cases, respectively. The odds of well-differentiated tumors in transcription marker immuno-positive cases were 45% lower compared to immuno-negative cases (OR = 0.55, 95% CI 0.32–0.96). The odds of positive lymph nodes were 2.01 times higher in CSC immuno-positive cases compared to immuno-negative cases (OR = 2.01, 95% CI 1.11–3.65). Mortality in immuno-positive cases was 121% higher than that in immuno-negative cases (HR = 2.21; 95% CI 1.16–4.21). Advanced tumor staging and grading, lymph node metastasis, and mortality were significantly associated with positive immunoexpression of CSC markers.


  • Open Access

    Are Survival Outcomes Different for Young and Old Patients with Oral and Oropharyngeal Squamous Cell Carcinoma? A Systematic Review and Meta-Analysis

    by Swagatika Panda, Neeta Mohanty, Saurav Panda, Lora Mishra, Divya Gopinath, Alkananda Sahoo, Sumanth Kumbargere Nagraj, Barbara Lapinska

    This systematic review and meta-analysis aims to address whether age can be a determinant of overall survival (OS), disease-free survival (DFS), recurrence, distant metastasis (DM) and second primary (SP) in surgically treated oral and oropharyngeal squamous cell carcinoma (OOPSCC). A total of 4981 cases and 44254 controls from 25 comparative observational studies were included in the analysis. A significantly better OS (matched subgroup analysis: OR 1.64; 95% CI 1.31–2.04, overall analysis: OR 1.48; 95% CI 1.09–2.01) was observed in young patients compared to older adults, with heterogeneity ranging from moderate to severe. Worse DFS (unmatched subgroup analysis OR 0.43; 95% CI 0.27–0.68) was observed in young patients compared to older adults with minimal to moderate heterogeneity. The frequency of recurrence (OR 1.49; 95% CI 1.10–2.02) and DM (OR 1.83; 95% CI 1.10–3.03) was significantly higher in the young patients, as found in unmatched and matched subgroup analysis, with the least heterogeneities. Young age can be considered as an independent prognostic factor for recurrence and distant metastases in OOP-SCC. Larger and methodologically robust observational studies with longer follow-up are needed to establish the definitive role of age as an independent prognostic factor on OS and DFS in OOPSCC.


  • Central Giant Cell Granuloma: Contradicting the Usual Picture

    by Alkananda Sahoo, Swagatika Panda, Subrat Padhiary, Neeta Mohanty, Debkant Jena

    Jaffe in 1953 differentiated Central Giant Cell Granuloma (CGCG) from Giant Cell Tumor of bone. This intra-osseous lesion has been described by various authors'as a reactive lesion or as a developmental anomaly or as a non neo-plastic lesion. Though inflammation, haemorrhage, local trauma has been suggested as some of the aetiological factors but actual aetiology is still unclear. Genetic aetiology has also been hypothesized. Mandible is the common site of occurrence, frequently crossing the midline. Incidences in females are more and less than 30 is the age of occurrence. The clinical behaviour of CGCG ranges from a slow-growing asymptomatic swelling to an aggressive lesion with pain, local osteolysis, root resorption and tooth displacement. Most widely accepted treatment is surgery. Nonsurgical treatments with alpha-interferon, calcitonin and corticosteroids have been described and their benefits may be worthy of consideration. Contrary to the age, gender and site here we present a case of CGCG in a 52-year-old male patient presenting with a swelling in the right anterior maxilla.